<DOC>
	<DOCNO>NCT02354599</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics pharmacodynamics single subcutaneous injection MT203 healthy adult Japanese Caucasian male participant .</brief_summary>
	<brief_title>Single-Dose Study MT203</brief_title>
	<detailed_description>The drug test study call MT203 ( Namilumab ) , human immunoglobulin G1 ( IgG1 ) mAb potently specifically neutralize human macaque granulocyte macrophage colony stimulate factor ( GM-CSF ) . This study consist Cohorts 1 3 healthy Japanese participant Cohort 4 healthy Caucasian participant . Each cohort comprise 8 participant , 6 participant randomize receive MT203 2 participant randomize receive match placebo . The study population study consist 24 Japanese 8 Caucasian healthy participant . Participants assign 4 cohort remain undisclosed patient study doctor study ( unless urgent medical need ) : : Cohort 1 : - MT203 80 mg ( 6 healthy Japanese participant ) ; Matching Placebo ( 2 healthy Japanese participant ) Cohort 2 : - MT203 150 mg ( 6 healthy Japanese participant ) ; Matching Placebo ( 2 healthy Japanese participant ) Cohort 3 : - MT203 300 mg ( 6 healthy Japanese participant ) ; Matching Placebo ( 2 healthy Japanese participant ) Cohort 4 : - MT203 150 mg ( 6 healthy Caucasian participant ) ; Matching Placebo ( 2 healthy Caucasian participant ) . Dosing Caucasian participant ( Cohort 4 ) may occur parallel dose Japanese participant ( Cohorts 1 3 ) . Dose escalation occur Japanese Cohorts , independent Cohort 4 . The dose escalation occur follow review blind safety/tolerability data Day 15 previous cohort . All participant receive single dose Day 1 , admit Day -1 Day 15 . Participants return study unit pharmacokinetic , pharmacodynamic safety assessment Days 22 , 29 , 43 , 57 , 71 85 . This trial conduct Japan.Overall time participate trial 85 day .</detailed_description>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant healthy adult male Japanese Caucasian ( born Caucasian parent grandparent ) . 4 . The participant age 20 45 year , inclusive , time informed consent . 5 . The participant weighs least 50 kilogram ( kg ) body mass index ( BMI ) 18.5 25.0 kilogram per square meter ( kg/m2 ) ( Japanese ) 18.5 30.0 kg/m2 ( Caucasian ) , inclusive screening Day1 . 6 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 18 week ( 126 day ) last dose . 1 . The participant receive investigational compound within 16 week ( 112 day ) prior first dose study medication . 2 . The participant receive MT203 antigranulocytemacrophage colony stimulate factor ( GMCSF ) drug previous clinical study . 3 . The participant vaccinate within 4 week ( 28 day ) prior first dose study medication schedule vaccinate study . 4 . The participant immediate family member , study site employee may consent duress . 5 . The participant uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , endocrine disease abnormality , may impact ability participant participate potentially confound study result . 6 . History frequent chronic infection herpes zoster . 7 . The participant history currently significant pulmonary disease , inflammatory disease autoimmune disease . 8 . The participant know hypersensitivity component formulation MT203 . 9 . The participant positive urine drug result drug abuse screen . 10 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior screen visit unwilling agree abstain alcohol drug throughout study . 11 . The participant take require excluded medication , supplement food product list Excluded Medications section throughout study . 12 . The participant intend donate sperm course study 18 week last dose study medication . 13 . The participant history cancer . 14 . Presence , suspicion history active tuberculosis ( TB ) latent TB infection . 15 . The participant positive test result hepatitis B virus ( HBV ) surface antigen ( HBsAg ) , hepatitis B virus antibody ( HBV surface virus antibody [ HBsAb ] / HBV core antibody [ HBcAb ] ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody/antigen screen . However , participant positive HBsAb due HBV vaccination exempt . 16 . The participant use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 4 week ( 28 day ) prior first dose study medication . 17 . The participant clinically relevant decrease lung function , example , force expiratory volume first second ( FEV1 ) less ( &lt; ) 70 percent ( % ) predict value . 18 . The participant poor peripheral venous access . 19 . The participant undergone whole blood collection least 200 milliliter ( mL ) within 4 week ( 28 day ) least 400 mL within 12 week ( 84 day ) prior first dose study medication . 20 . The participant undergone whole blood collection least 800 mL total within 52 week ( 364 day ) prior first dose study medication . 21 . The participant undergone blood component collection within 2 week ( 14 day ) prior start study medication administration . 22 . Participant abnormal ( clinically significant ) electrocardiogram ( ECG ) screen Day 1 . 23 . The participant abnormal laboratory value screen Day1 suggest clinically significant underlying disease participant follow laboratory abnormality : Alanine transaminase ( ALT ) and/or aspartate transaminase ( AST ) great ( &gt; ) 1.5 time upper limit normal neutrophil count and/or monocyte count &lt; low limit normal . 24 . Participant , opinion investigator , unlikely comply protocol unsuitable study reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Randomized , double-blind , placebo-controlled , single-dose subcutaneous administration study</keyword>
</DOC>